
Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.
Peter Lio, M.D., is assistant professor of clinical dermatology and pediatrics at Northwestern University’s Feinberg School of Medicine, and private practice, Dermatology and Aesthetics of Wicker Park, Wicker Park, Chicago.

Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.

Peter Lio, MD, explains the importance of having a wide-range of solutions and how he incorporates alternative approaches alongside conventional medicine.

Peter Lio, MD, expands on dosing considerations to treat atopic dermatitis with involvement on the hands and feet for different ages, weights, lifestyles, and more.

Peter Lio, MD, takes a deep dive into the results of the 3 LIBERTY-AD-HAFT study and how it impacts the treatment of hand-foot atopic dermatitis.

Lio spoke with Dermatology Times to discuss his sessions at AAD 2024, including addressing systemic malignancies with alternative or adjunctive therapies and the importance of minimizing pain in dermatology procedures.

Lio delves into his American Academy of Dermatology Annual Meeting session, "Dietary Triggers and Modifications of Common Dermatologic Conditions: An Evidence Based Approach."

An expert in the management of skin conditions highlights the case of a 45-year-old female with severe pruritus, erythematous rash, and lichenification across multiple body areas, worsened by recent work-related stress from a promotion. Dr. Lio offers insights into managing such patients and shares practical tips for a streamlined prescription process.

Peter Lio, MD, presents the case of a 56-year-old female with a history of severe atopic dermatitis and very dry skin. Dr. Lio discusses the significance of accurate disease diagnosis, tools for assessing severity, and the array of treatment options available for this patient. He emphasizes the importance of shared decision-making in managing the condition.

A patient with atopic dermatitis presents with redness and other unusual symptoms. What's the diagnosis?

Experts discuss prospective therapies on the horizon for atopic dermatitis (AD).

Experts offer their clinical experience on preventing patient withdrawal and breaking the atopic dermatitis (AD) disease cycle.

Peter Lio, MD also explained why he considers it a bad day when he does not learn something new about this disease.

Peter Lio, MD, FAAD, discusses how body surface area of atopic dermatitis (AD) affects topical treatment options.

Shawn Kwatra, MD, offers important considerations for providers when utilizing topical therapies for atopic dermatitis (AD).

Experts discuss the history and evolving landscape of topical steroids as therapy for atopic dermatitis (AD).

Peter Lio, MD, FAAD, and Shawn Kwatra, MD, discuss janus kinase (JAK) inhibitors and their recent use in the treatment of atopic dermatitis (AD).

Experts discuss the symptoms of atopic dermatitis (AD) and how disease severity may impact symptoms.

Shawn Kwatra, MD, and Peter Lio, MD, FAAD, discuss the burden of atopic dermatitis (AD) and how it may affect pediatric or adult patients.

Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.

Experts share insight on the challenges inherent in treating patients with atopic dermatitis despite recent advances in therapy.

Concluding their focused discussion on JAK inhibitors in atopic dermatitis, panelists share advice on the optimal selection based on route of administration and use of these agents.

A brief review of 2 oral JAK inhibitors recently approved for patients with atopic dermatitis.

A panel of experts review the use of topical ruxolitinib in atopic dermatitis, shedding light on safety and efficacy considerations.

Focusing on JAK inhibitors, panelists consider the historical use of these agents in atopic dermatitis and their corresponding mechanisms of action.

Experts define stages of atopic dermatitis and share insight on the conventional treatment landscape for mild to moderate and moderate to severe atopic dermatitis.

Expert perspectives on the nature of atopic dermatitis, ranging from diagnosis and pathophysiology to the clinical and social burden it places on patients.

In our first Irregular Borders column, Peter A. Lio, M.D., explores the evidence for leaky gut and its relevance in dermatology while highlighting parallels with impaired skin barrier function in conditions such as atopic dermatitis.

Healthcare disparities exist in all fields of medicine, including dermatology. We seek to address these disparities in this article by outlining the differences in epidemiology, presentation, access and outcomes of five conditions in patients with skin of color.

In this article, Dr. Peter A. Lio discusses how recent advances in atopic dermatitis have led to a new standard of care, which aims to keep patients clear safely and maximize improvements in quality of life.

Some unconventional therapies for rosacea get to the root of the problem, with apparent positive impacts on inflammation, skin barrier dysfunction and vascular function.